Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
2 results
Search Results
Item The Health Impact Projection Model Of The Pd-1/Pd-L1 Inhibitor Class In Cancer Care In Turkey(2022) Akpamuk, U.; Hughes, R.; Swales, O.; Oyan, B.; Kilickap, S.; Demirci, U.; Sendur, M.A.; Sonmez, O.; Yazici, O.; Malhan, S.; Oksuz, E.; Tuzer, E.; Ersoy, Akyol B.; Poellinger, B.Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.